Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-330-3001 Phase 3 Trial in Urgent Surgery for Factor Xa Inhibitor Reversal
2022-503012-16-00Phase 3Authorised
- Sponsor
- Takeda
- Start
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of Prothromplex Total in coagulopathy (2 arms), sponsored by Takeda. Primary endpoint: Occurrence of intraoperative effective hemostasis (Four Point Intraoperative Hemostatic Efficacy Scale). Planned start Jul 2022; status: authorised.
02
Drugs
Prothromplex Total
03
Conditions
coagulopathy
Beyond the preview
Go deeper on 2022-503012-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503012-16-00.